Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stimotimagene copolymerplasmid with Ganciclovir in Advanced Solid Tumors
NCT05578820Phase 1Completed
- Sponsor
- Gene Surgery LLC
- Start
- Jan 2022
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Polymer-based Nanoparticles, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of stimotimagene copolymerplasmid in sarcoma, melanoma, head and neck squamous cell carcinoma (HNSCC) and 5 more (3 arms), sponsored by Gene Surgery LLC. Primary endpoints: Dose-Limiting Toxicities at 1 year, Adverse Events at 1 year and 3 more. Started Jan 2022; status: completed.
02
Drugs
stimotimagene copolymerplasmid
03
Conditions
sarcomamelanomahead and neck squamous cell carcinoma (HNSCC)breast cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT05578820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578820.